FLT3 and acute myeloid leukemia: Ras pathway mutations are highly prevalent in relapsed acute leukemia, especially in pediatric AML where it can represent up to 30% of cases, as KRAS, NRAS, fms-like tyrosine kinase 3 (FLT3) or PTPN11 mutations [5].